Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 238

The DOI matches its Crossref record.

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

Open access
Tolcher, Anthony W., Mita, Alain, Lewis, Lionel D., Garrett, Christopher R., Till, Elizabeth, Daud, Adil I., Patnaik, Amita, Papadopoulos, Kyri, Takimoto, Chris, Bartels, Pamela, Keating, Anne, Antonia, Scott · 2008 · Journal of Clinical Oncology

Abstract

Purpose: To determine the maximum-tolerated dose (MTD) and assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of YM155, a small-molecule inhibitor of survivin. Patients and Methods: Patients with advanced solid malignancies or lymphoma were treated with escalating doses of YM155 administered by 168-hour continuous intravenous infusion (CIVI). Plasma and urine samples were assayed to determine pharmacokinetic parameters and excretion. Results: Forty-one patients received 127 cycles of YM155 at doses ranging from 1.8 to 6.0 mg/m 2/d by 168-hour CIVI every 3 weeks. Overall, the most common grade 1 to 2 toxicities were stomatitis, pyrexia, and nausea, whereas grade 3 and 4 toxicities were rare. Reversible elevation in serum creatinine in two patients, with one developing acute tubular necrosis, was dose-limiting at 6.0 mg/m 2. The MTD was 4.8 mg/m 2. At the MTD, the mean steady-state concentration, clearance, volume of distribution at steady-state, and terminal elimination half-life were 7.7 ng/mL, 47.7 L/h, 1,763 L, and 26 hours, respectively. One complete and two partial responses lasting 8, 24+ and 48+ months occurred in three patients with non-Hodgkin's lymphoma, two patients with hormone- and docetaxel-refractory prostate cancer had prostate-specific antigen responses, and one patient with non–small-cell lung cancer had a minor response. Conclusion: YM155 can be administered safely at 4.8 mg/m 2/d 168 hours CIVI every 3 weeks. The absence of severe toxicities, attainment of plasma concentrations active in preclinical models, and compelling antitumor activity warrant further disease-directed studies of this agent alone and in combination with chemotherapy in a broad array of tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.17.2064

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 238

Metadata

Authors
Tolcher, A. W., Mita, A., Lewis, L. D., Garrett, C. R., Till, E., Daud, A. I., Patnaik, A., Papadopoulos, K., Takimoto, C., Bartels, P., Keating, A., & Antonia, S.
Venue
Journal of Clinical Oncology
Published
2008-11-10
Volume
26
Issue
32
Pages
5198-5203
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2087681835
Cited by
238
References
0
FWCI
10.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin. https://app.cochat.ai/papers/10.1200/jco.2008.17.2064
The paper
Tolcher, A. W., Mita, A., Lewis, L. D., Garrett, C. R., Till, E., Daud, A. I., Patnaik, A., Papadopoulos, K., Takimoto, C., Bartels, P., Keating, A., & Antonia, S. (2008). Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.17.2064

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.